24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

7595 General Poster Session (Board #51E), Sat, 1:15 PM-5:15 PM<br />

Survival outcome segregated by KRAS mutation status in newly diagnosed<br />

stage IV non-small cell lung cancer (NSCLC) patients (pts) treated with<br />

first-line chemotherapy. Presenting Author: Anna K. Brady, University <strong>of</strong><br />

Pennsylvania, Philadelphia, PA<br />

Background: KRAS mutations (MT) form a distinct subset <strong>of</strong> NSCLC,<br />

generally considered to have poor prognosis. Although KRAS MT is a<br />

well-establised prognostic and predictive marker in colorectal cancer, its<br />

role in NSCLC remains ambiguous. Pts with KRAS MT NSCLC do not<br />

respond well to epidermal growth factor receptor (EGFR) directed tyrosine<br />

kinase inhibitor therapy, but little is known about the ability <strong>of</strong> KRAS MT to<br />

predict outcome after first-line chemotherapy in newly diagnosed advanced<br />

or recurrent NSCLC. Methods: We analyzed outcomes <strong>of</strong> consecutive pts<br />

with newly identified Stage IV non- squamous NSCLC treated at University<br />

<strong>of</strong> Pennsylvania (Penn) between 05/2008 and 7/2010 and then compared<br />

survival based on KRAS status [MT vs wild type (WT)] using chi square,<br />

Kaplan-Meier methods, and Cox regression models. Results: Of 106<br />

consecutive new pts with Stage IV non squamous NSCLC treated at Penn,<br />

49 (46%) underwent molecular analysis for KRAS MT. Fifteen (34%) were<br />

KRAS MT. Of 34 KRAS WT pts, 6 were positive for EGFR MT. The median<br />

age <strong>of</strong> all 49 pts was 61 years; 83% were Caucasian, 45% male and 60%<br />

had a �10 pack year smoking history. Median duration <strong>of</strong> follow up is 16.4<br />

mos. Majority <strong>of</strong> pts (92%) had adenocarcinoma histology. Most pts (88%)<br />

had ECOG PS 0-1 at presentation. Forty three pts received first line<br />

platinum-based combination chemotherapy (platinum and pemetrexed in<br />

31 pts). KRAS MT was associated with smoking (p�0.04), but not with<br />

gender or age. Overall survival (OS) <strong>of</strong> pts with KRAS MT was similar to<br />

KRAS WT pts [median OS 15.6 vs. 19.0 mos; HR 1.24 (95% CI<br />

0.57-2.67)]. Univariate analyses demonstrated superior OS among women<br />

compared to men (HR 0.40, 95% CI 0.20-0.85) in the entire pt cohort.<br />

Conclusions: In our population <strong>of</strong> stage IV non squamous NSCLC, pts with<br />

KRAS MT had similar OS to those with KRAS WT tumors. OS was slightly<br />

higher in KRAS WT pts, but this may have been confounded by the<br />

inclusion <strong>of</strong> 6 EGFR MT pts in this cohort. The potential prognostic or<br />

predictive role <strong>of</strong> KRAS MT in NSCLC pts undergoing chemotherapy<br />

requires further prospective study.<br />

7597 General Poster Session (Board #51G), Sat, 1:15 PM-5:15 PM<br />

Insulin-like growth factor 1 (IGF-1R) protein expression (PE) and gene copy<br />

number (GCN) for discrimination <strong>of</strong> response and outcome to figitumumab<br />

in NSCLC. Presenting Author: Murry W. Wynes, Division <strong>of</strong> Medical<br />

Oncology, University <strong>of</strong> Colorado Denver, Aurora, CO<br />

Background: Early clinical data suggested figitumumab (F), an anti-IGF-1R<br />

antibody, had clinical activity in several tumor types. However, two phase<br />

III studies, A4021016 carboplatin/paclitaxel (CP) �/- F in 1st line<br />

treatment or A4021018 erlotinib (E) �/- F in 2nd line therapy for patients<br />

with advanced NSCLC, were closed prematurely due to futility. Neither<br />

study used biomarker driven selection criteria. The aim <strong>of</strong> this study was to<br />

retrospectively examine the phase III specimens in order to determine if<br />

IGF-1R PE or GCN could discriminate response and/or outcome to F.<br />

Methods: IGF-1R PE was determined by immunohistochemistry (IHC) and<br />

the tumor specimens were scored using the H-score method (0-300) with<br />

separate enumeration <strong>of</strong> membranous and cytoplasmic components and<br />

then combination <strong>of</strong> these scores. GCN was evaluated by bright field silver<br />

in situ hybridization (SISH) with recording the average copy number for 50<br />

tumor cells. Results: IHC was evaluable in 25 CP�F, 20 CP, 27 E�F and<br />

26 E specimens whereas SISH was evaluable in 24, 17, 21 and 22<br />

specimens, respectively. Median PE for membrane, cytoplasm and both in<br />

A4021016 were 130, 110 and 120 and in A4021018 they were 135, 140<br />

and 140. Median GCN was 1.88 and 1.98 for A4021016 and A4021018,<br />

respectively. There were no significant differences in PE or GCN between<br />

treatment arms within each study. Neither PE nor GCN were able to<br />

discriminate between response/non-response or disease control/progression<br />

in either study. Likewise, neither study showed a significant difference<br />

in OS or PFS when using the median cut-points for either PE or GCN.<br />

Conclusions: Neither IGF1R PE or GCN were able to discriminate response<br />

or outcome in the limited quantity <strong>of</strong> specimens available from two studies<br />

that examined the IGF-1R targeted therapy figitumumab.<br />

Lung Cancer—Non-small Cell Metastatic<br />

7596 General Poster Session (Board #51F), Sat, 1:15 PM-5:15 PM<br />

Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced<br />

non-small cell lung cancer (NSCLC) patients treated with crizotinib.<br />

Presenting Author: Ravi Salgia, The University <strong>of</strong> Chicago, Chicago, IL<br />

Background: Crizotinib is an ALK inhibitor indicated in the US for advanced<br />

ALK-positive NSCLC. Visual effects reported by patients treated with<br />

crizotinib were characterized using the Visual Symptom Assessment<br />

Questionnaire (VSAQ). Methods: Patients with previously treated, advanced<br />

ALK-positive NSCLC were administered 250 mg BID crizotinib in an<br />

ongoing phase II study (PROFILE1005, NCT00932451; Pfizer). Patients<br />

completed the VSAQ at day 1 <strong>of</strong> each 21 day cycle and at end <strong>of</strong> treatment.<br />

The VSAQ has a recall period <strong>of</strong> 3 weeks and consists <strong>of</strong> 7 questions<br />

assessing presence, frequency, timing, duration and degree <strong>of</strong> bother <strong>of</strong><br />

visual effects and their impact on Activities <strong>of</strong> Daily Living (ADL). The<br />

visual effects assessed included appearance <strong>of</strong> overlapping shadows/after<br />

images, flashing lights and streamers/strings/floaters, difficulty adapting to<br />

lights and seeing at night. Patients rated degree <strong>of</strong> bother on a 5-point scale<br />

ranging from ‘not at all’ to ‘extremely’. Impact on ADL was measured using<br />

a 10-point scale (0: no effect; 10: completely prevented ADL). Frequency<br />

analyses were performed. Results: As <strong>of</strong> June 1 2011, visual effects as<br />

identified by VSAQ were reported by 63% (114/182) <strong>of</strong> patients at cycle 2<br />

(C2), 57% at C3 (85/149), 52% at C4 (64/123) and 41% at C5 (46/112).<br />

The most commonly experienced visual events were appearance <strong>of</strong> flashing<br />

lights (C2:81%; C3:82%; C4:84%; C5: 76%), streamers/strings/floaters<br />

(C2: 83%; C3:78%; C4: 81%; C5:87%) and overlapping shadows/after<br />

images (C2:70%; C3:77%; C4:87%; C5:84%). Most patients reported<br />

each event to last �1 minute (C2:61%; C3:71%; C4:77%; C5: 70%).<br />

Majority <strong>of</strong> patients reported event frequency at each cycle <strong>of</strong> � 7 days/wk<br />

(50–78%). Patients reported that the visual effects occurred mostly in the<br />

morning (52–62%) and/or evening (62–73%). Majority <strong>of</strong> patients reported<br />

that visual effects were not at all or a little bothersome (C2:62%;<br />

C3:61%; C4:66%; C5:65%). Majority <strong>of</strong> patients indicated no or minimal<br />

impact on ADL (C2:80%; C3:80%; C4:83%; C5:87%). Conclusions: Visual<br />

effects identified by VSAQ in patients treated with crizotinib were frequent,<br />

but were reported to be transient with no or minimal impact on ADL.<br />

7598 General Poster Session (Board #51H), Sat, 1:15 PM-5:15 PM<br />

<strong>Clinical</strong> presentation <strong>of</strong> hepatotoxicity-associated crizotinib in ALKpositive<br />

(ALK�) advanced non-small cell lung cancer (NSCLC). Presenting<br />

Author: Patrick Schnell, Pfizer Inc., New York, NY<br />

Background: Severe hepatotoxicity has been observed with most receptor<br />

tyrosine kinase inhibitors. Crizotinib, a first-in-class oral inhibitor <strong>of</strong> ALK,<br />

was recently FDA approved for the treatment (tx) <strong>of</strong> advanced (ALK�)<br />

NSCLC. We provide a review <strong>of</strong> hepatotoxicity in the crizotinib clinical<br />

development program. Methods: Relevant tx-emergent adverse event (AE)<br />

reports from 2 pooled single-arm trials in patients (pts) with ALK� NSCLC<br />

who received crizotinib 250 mg BID (n�588) up to Jun 2011 were<br />

reviewed. Five reports <strong>of</strong> severe hepatotoxicity received through Dec 13,<br />

2011 were also evaluated. Results: Incidence <strong>of</strong> elevation in ALT and AST<br />

lab values by CTCAE grade are shown in the table. Additionally, 16<br />

all-grade (7 grade 3 or 4) cases <strong>of</strong> pertinent hepatic events have been<br />

reported. Transaminase elevations generally occurred in the first 2 months<br />

<strong>of</strong> tx and were usually reversible. Pts usually resumed tx at a lower dose<br />

without recurrence; however, 4 (�1%) required permanent discontinuation<br />

from tx. Five (�1%) cases <strong>of</strong> severe, potentially drug-related hepatotoxicity<br />

(2 fatal) were reported through Dec 13, 2011, with an estimated exposure<br />

<strong>of</strong> 1400 pts. Pts presented with fatigue, nausea, anorexia, weakness, and<br />

abdominal pain. Time from starting crizotinib to onset <strong>of</strong> hepatotoxicity was<br />

�6 weeks in 4 cases, while significant transaminase elevation was<br />

observed after 6 months in the fifth case. Significant hepatic metastases<br />

and abnormal enzymes at baseline were present in 1 (fatal) case, while<br />

baseline transaminases were normal in 3 cases, or just above the upper<br />

limit <strong>of</strong> normal in 1 case. Conclusions: Crizotinib is uncommonly associated<br />

with severe hepatotoxicity and was reported in �1% <strong>of</strong> pts. Nausea,<br />

malaise, decreased appetite, vomiting, and abdominal pain may indicate<br />

hepatic toxicity. ALT and total bilirubin should be monitored monthly and<br />

as clinically indicated. Discontinuation <strong>of</strong> crizotinib is recommended when<br />

severe drug-induced hepatic toxicity is suspected or diagnosed.<br />

Causality/grade<br />

N � 588<br />

Increased ALT<br />

n (%)<br />

503s<br />

Increased AST<br />

n (%)<br />

All causality<br />

All grade 86 (14.6) 63 (10.7)<br />

Grade 3/4 30 (5.1) 14 (2.4)<br />

Tx related<br />

All grade 73 (12.4) 52 (8.8)<br />

Grade 3/4 24 (4.1) 10 (1.7)<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!